Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease
Open Access
- 27 March 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 115 (12), 1528-1536
- https://doi.org/10.1161/circulationaha.106.649939
Abstract
Background— Data supporting the prognostic significance of high-sensitivity C-reactive protein (hs-CRP) are derived largely from individuals with no overt coronary artery disease or from patients with acute coronary syndromes. In contrast, the ability of hs-CRP to predict outcomes in patients with stable coronary artery disease and the prognostic significance of the Centers for Disease Control/American Heart Association hs-CRP cut points in such a population remain relatively unexplored. Methods and Results— We measured hs-CRP in 3771 patients with stable coronary artery disease from the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) trial, a randomized placebo-controlled trial of the angiotensin-converting enzyme inhibitor trandolapril. Patients were followed up for a median of 4.8 years for cardiovascular death, myocardial infarction, or stroke, as well as new heart failure and diabetes. After adjustment for baseline characteristics and treatments, higher hs-CRP levels, even >1 mg/L, were associated with a significantly greater risk of cardiovascular death, myocardial infarction, or stroke (hs-CRP 1 to 3 mg/L: adjusted hazard ratio, 1.39; 95% CI, 1.06 to 1.81; P =0.016; hs-CRP >3 mg/L: adjusted hazard ratio, 1.52; 95% CI, 1.15 to 2.02; P =0.003). Similarly, elevated hs-CRP levels were an independent predictor of new heart failure (adjusted P P Conclusions— In stable coronary artery disease, an elevated hs-CRP level, even >1 mg/L, is a significant predictor of adverse cardiovascular events independently of baseline characteristics and treatments. An elevated hs-CRP does not appear to identify patients with stable coronary artery disease and preserved ejection fraction who derive particular benefit from angiotensin-converting enzyme inhibition.Keywords
This publication has 35 references indexed in Scilit:
- Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor TrialCirculation, 2006
- Valsartan, Blood Pressure Reduction, and C-Reactive ProteinHypertension, 2006
- Binding and Internalization of C-Reactive Protein by Fcgamma Receptors on Human Aortic Endothelial Cells Mediates Biological EffectsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery DiseaseThe New England Journal of Medicine, 2004
- Is Type 2 Diabetes Mellitus a Vascular Condition?Arteriosclerosis, Thrombosis, and Vascular Biology, 2003
- C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth MuscleCirculation, 2003
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003
- Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design)The American Journal of Cardiology, 1998
- IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin ResistanceScience, 1996
- A study of C-reactive protein in the serum of patients with congestive heart failureAmerican Heart Journal, 1956